Third Annual Oxford RNAi Conference
RNAi2008 – Functions and Applications of Non-coding RNAs
13-14 March 2008, St. Anne’s College, Osford, UK
The Third Annual Oxford RNAi Conference, RNAi2008, will address most aspects of biology and application of RNA interference. The conference is aimed at bringing together leading experts in the field from both academia and industry, postdoctoral scientists, graduate research students and research managers. Thus this event provides an excellent opportunity to discover the latest research directions and thinking in this fast moving field in academic and commercial settings, as well as to develop new collaborative links.
Association of Biomolecular Resource Facilities (ABRF)
Enabling Technologies in the Life Sciences
February 9-12, 2008
Salt Palace Convention Center
Salt Lake City, Utah
In addition to our usual emphasis on genomics and proteomics we have expanded our focus to include related technology such as flow cytometry, microscopy and imaging, laser capture micro dissection, lipidomics, ion mobility mass spectrometry and more.
The ABRF Annual Meeting was recently named one of the “Big Ten Conferences” and rates the Most Recommended Meeting for Technology & Instrumentation” by the readers of Genome Technology
Save 15% from MedBioWorld when you shop at any of Lippincott Williams & Wilkins/Wolters Kluwer specialty stores!
41st Miami Winter Symposia, Regulatory RNA in Biology and Human Health
February 3, 2008 – February 6, 2008
Miami Beach Resort & Spa Hotel
4833 Collins Avenue
Miami Beach, FL, 33140, USA.
Fourth Annual PEGSummit
April 28 – May 02, 2008
Phage Display of Peptides and Antibodies
Clinical Development of Therapeutic Antibodies
Difficult to Express Proteins
Assessment of Immunogenicity in Clinical Trials
Engineering Protein Therapeutics for Delivery
Protein Scale-Up & Manufacturing
NIH – Limited Competition: Construction of a Reference Sequence Data Set for the Human Microbiome Project (U54)
Request For Applications (RFA) Number: RFA-RM-08-001
Release Date: November 21, 2007
Letters of Intent Receipt Date: April 22, 2008
Application Receipt Date: May 22, 2008
Peer Review Date(s): October/November, 2008
Council Review Date: January 2009
Earliest Anticipated Start Date: April 1, 2009
Expiration Date: May 23, 2008
Applicant information meeting: December 10, 2007 (see http://www.scgcorp.com/Microbiome)
-This RFA invites applications for a limited competition Request for Applications (RFA) for the continued support of sequencing efforts to complete the generation of a reference set of DNA sequence-based data for the Human Microbiome Project (HMP).
-The overall objective of this limited competition RFA is to support continued generation of sequenced microbial genomes isolated from the human body and exploration, through metagenomic sequencing, of the microbial flora at a set of designated anatomical sites of the human body.
-This limited competition RFA will use the U54 cooperative agreement mechanism to continue the effort of supporting human microbiome sequencing that was begun in FY07 through funds provided to NHGRI- and NIAID-funded large-scale sequencing centers.
-The total funds available for up to five awards are approximately $30,542,500 total costs for four years.
-Up to 5 awards are anticipated from this FOA.
-Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); Eligible Agencies of the Federal Government.
-Only NHGRI and NIAID awardees of large-scale sequencing centers (both extramural and intramural; e.g. those Institutions currently funded under RFA-06-001) are invited to apply.
-Eligible principal investigators include the current principal investigator and/or any other designated/approved individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research.
-See Section IV.1 for application materials.
-Telecommunications for the hearing impaired is available at: TTY 301-451-0088.
-Special Receipt Date May 22, 2008
microRNA in Human Disease and Development
miRNA as Diagnostic Biomarkers and Targets for Therapeutic Development
Brought to you by Cambridge Healthtech Institute
March 10-11, 2008
Royal Senesta Boston Hotel
Register by December 14th and Save up to $350
FEATURED TOPICS INCLUDE:
microRNA Mechanism of Action
Role of microRNA in Oncology, Cardiology and Stem Cells
Tools and Technologies for microRNA Analysis
microRNA as Diagnostic Biomarkers
microRNA as Targets for Therapeutic Development
Coordinate Gene Regulation during Hematopoiesis Is Related to Genomic Organization
How are genomesâ€”and the chromosomes that comprise themâ€”organized in the eukaryotic nucleus? This long-standing question in cell biology has gained renewed interest due to observations that gene regulation is correlated with the nonrandom distribution of gene loci linearly along chromosomes and spatially within the nucleus. We have used an in vitro model of cellular differentiation to test the hypothesis that there is an inherent organization of the genome related to coordinate gene regulation. Our analysis reveals that during the differentiation of a murine hematopoietic (blood-forming cell) progenitor to derived cell types, co-regulated genes have a marked tendency to be proximal along chromosomes in the form of clusters (of two and three genes) and large-scale domains. Overall gene expression is also spatially proximal, with a pronounced concentration in the nuclear center. The chromosomes themselves parallel this organization of gene activity, with chromosome territories localizing primarily in the interior of the nucleus. Surprisingly, we found that homologous chromosomes have a tendency to be associated, the extent of which is related to the number of co-regulated genes residing on the particular chromosome. Furthermore, individual gene domains display lineage-specific proximity according to their co-regulation. Our study supports the idea that the eukaryotic nucleus is broadly organizedâ€”with proximity playing a key roleâ€”to facilitate coordinated gene regulation during cellular differentiation.
Received: July 10, 2006; Accepted: September 25, 2007; Published: November 20, 2007
Genome Evolution and Structural Variation: Next Steps in Natural Human Genetic Variation
November 28, 2007
The Sheraton Seattle Hotel
Seattle, Washington, USA
This one day idea-generating meeting will draw on Seattle’s research community, and invited speakers from the fields of human genetic variation and evolution. Discussion will focus on the overall question of the next steps in characterizing human genetic variation and genome evolution. Speakers will focus on challenges related to their topic, such as incorporating structural variation detection into current technologies, or within current large-scale projects to characterize natural genetic variation.
“Pushing the limits”: 2007 Congress of the Swiss Proteomics Society
To be held at the “Ecole HoteliÃ¨re de Lausanne, Lausanne, Switzerland”
December 3rd to 5th 2007.
The SPS07 congress will focus on the present limitations in the field of proteomics, and in particular on how can we go beyond the limits.
Presentations will cover areas such as:
In vivo proteomics
Bioinformatics and statistics
Presentations by an international panel of speakers will address these and other important issues, in order to give a clear picture of the directions of proteomics research in which we can push the limits.
Public Meeting to Request Information and Comment from Industry concerning the use of RNAi Technologies in the NIH Intramural Laboratories
Release Date: October 30, 2007
Submission Due Date: December 3, 2007
Response Date: December 10, 2007 (approximate)
Meeting Date: December 17, 2007
RNAi technologies are an exciting and rapidly evolving technique to determine the functions of genes and transcripts.
NIH will establish a Trans-NIH effort to facilitate both moderate (RNAi reagents targeting 10s to 100s of genes) and high throughput screens that ultimately target entire genomes.
The NIH intramural program seeks to facilitate NIH-wide utilization of RNAi technologies. This effort should support moderate- and high-throughput use. Information for either, or both, is requested.
NIH is seeking firms/suppliers who will enter into pricing arrangements with the NIH to support this research.